...March 5, 2026 This report does not constitute a rating action. Sales growth remains below expectations, and more divestitures may occur. Sales for the fiscal year ended Dec 31, 2025, declined 5.2% year-over-year, primarily because of the sale of its Pharma Solutions business midway through the year. Adjusting for divestitures, sales increased 1% year-over-year on a comparable-currency basis. This is lower than the 6% comparable sales growth in 2024 and below the company's long-term mid-single-digit percent target. We don't expect sales to grow again until at least 2027, as the company still has to lap last year's divestitures and could close on additional divestitures. The company is evaluating strategic alternatives for its Ingredient Solutions segment. Our projection assumes this segment remains with International Flavors & Fragrances (IFF) and will continue to grow below the underlying long- term growth expectations of 3%-4% of the company's other segments. Margins remain stable. The...